Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington. Show more

Location: The Omeros Building, Seattle, WA, 98119, United States | Website: https://www.omeros.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

175.8M

52 Wk Range

$2.97 - $13.60

Previous Close

$3.00

Open

$2.99

Volume

1,367,327

Day Range

$2.95 - $3.20

Enterprise Value

538.4M

Cash

52.41M

Avg Qtr Burn

-35.72M

Insider Ownership

4.40%

Institutional Own.

47.30%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Narsoplimab (OMS721) Details
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

PDUFA

Approval decision

Phase 3

Update

Phase 2

Data readout

Phase 2

Update

Phase 1b

Data readout

OMS1029 (MASP-2) Details
Lectin pathway disorder

Phase 1

Update

Narsoplimab (MASP-2 inhibitor, lectin pathway) Details
Kidney disease, Diabetic macular edema, Diabetes

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued